[{"data":1,"prerenderedAt":232},["ShallowReactive",2],{"\u002Fblog\u002Fpharma-does-not-need-a-new-ai-governance-religion":3},{"id":4,"title":5,"author":6,"body":7,"category":214,"date":215,"description":216,"draft":217,"excerpt":218,"extension":219,"heroImage":218,"heroImageAlt":218,"meta":220,"navigation":221,"path":222,"seo":223,"slug":218,"stem":224,"tags":225,"__hash__":231},"blog\u002Fblog\u002Fpharma-does-not-need-a-new-ai-governance-religion.md","Pharma Does Not Need a New AI Governance Religion","QikSolve",{"type":8,"value":9,"toc":204},"minimark",[10,14,19,22,26,29,70,73,77,80,158,162,169,173,176,179,183],[11,12,13],"p",{},"Most industries are still working out how to implement and govern AI. Pharma is in a different\nposition. In GMP environments, governance is already an operating discipline. The Pharmaceutical\nQuality System, supported by Quality by Design, Critical to Quality attributes, and process\nparameter control, already provides a practical foundation for governing a new type of worker: the\nAI agent. The opportunity is not to invent a parallel governance stack. It is to map AI agent\nmanagement maturity to quality management maturity, and run it with the same rigour already applied\nto every other regulated process.",[15,16,18],"h2",{"id":17},"pharma-already-speaks-the-language","Pharma already speaks the language",[11,20,21],{},"Recent agentic-AI direction from major platform vendors emphasises lifecycle controls, trust\nboundaries, layered verification, and continuous evaluation for AI agents. For pharma teams, that is\nnot unfamiliar territory — it maps closely to existing GMP operating logic: define intended use and\nquality objectives up front; control the process conditions that materially influence quality\noutcomes; verify continuously against defined critical-to-quality attributes; and act on drift with\ncorrective action when performance deviates from approved operating ranges. That is already how\nmature quality systems are managed. The vocabulary of AI agent governance and GMP governance are, in\npractice, the same.",[15,23,25],{"id":24},"governance-is-a-systems-view-not-a-model-check","Governance is a systems view, not a model check",[11,27,28],{},"When an AI agent participates in a regulated workflow, governance cannot rely on isolated model\nchecks alone — the full operating system has to be brought under control:",[30,31,32,40,46,52,58,64],"ul",{},[33,34,35,39],"li",{},[36,37,38],"strong",{},"Role and intended use:"," a clearly defined function within the regulated workflow, with\ndocumented decision boundaries and scope limitations.",[33,41,42,45],{},[36,43,44],{},"Approved data and tool boundaries:"," explicit allow-lists for data sources, retrieval scope,\nand tool permissions, controlled rather than assumed.",[33,47,48,51],{},[36,49,50],{},"Execution controls:"," runtime configuration, model version, prompt version, and fallback\nrouting treated as controlled parameters.",[33,53,54,57],{},[36,55,56],{},"Human review points:"," mandatory review gates at compliance-critical decision points, with\nevidence of review captured.",[33,59,60,63],{},[36,61,62],{},"Evidence and traceability:"," audit-ready provenance records for every agent output used in a\nregulated decision.",[33,65,66,69],{},[36,67,68],{},"Change control and revalidation:"," formal lifecycle gates for model updates, prompt changes,\nand configuration modifications.",[11,71,72],{},"That is a systems view, and it aligns directly with the quality-system principles already embedded\nin mature pharmaceutical organisations.",[15,74,76],{"id":75},"a-five-level-maturity-map","A five-level maturity map",[11,78,79],{},"AI agent management maturity maps directly to QMS maturity levels, with a characteristic governance\nsignal at each stage:",[81,82,83,99],"table",{},[84,85,86],"thead",{},[87,88,89,93,96],"tr",{},[90,91,92],"th",{},"Level",[90,94,95],{},"QMS analogue",[90,97,98],{},"Typical signal",[100,101,102,114,125,136,147],"tbody",{},[87,103,104,108,111],{},[105,106,107],"td",{},"1 — Ad hoc",[105,109,110],{},"Reactive quality posture",[105,112,113],{},"Inconsistent output quality, low traceability",[87,115,116,119,122],{},[105,117,118],{},"2 — Documented",[105,120,121],{},"Basic defined system",[105,123,124],{},"Repeatable process, fragile under variation",[87,126,127,130,133],{},[105,128,129],{},"3 — Controlled",[105,131,132],{},"Managed quality system",[105,134,135],{},"Stable operation with auditable evidence",[87,137,138,141,144],{},[105,139,140],{},"4 — Predictive",[105,142,143],{},"Capable quality system",[105,145,146],{},"Risks detected before quality failure occurs",[87,148,149,152,155],{},[105,150,151],{},"5 — Optimised",[105,153,154],{},"Continuous-improvement maturity",[105,156,157],{},"Sustained performance improvement, controlled risk",[15,159,161],{"id":160},"applying-quality-by-design-to-agents","Applying Quality by Design to agents",[11,163,164,165,168],{},"Before any AI agent enters a regulated workflow, teams can define an ",[36,166,167],{},"Agent Quality Target\nProfile"," — the agent equivalent of a product quality target profile: intended role, decision\nboundaries, required evidence outputs, acceptable failure modes, and mandatory human checkpoints.\nCritical-to-quality attributes for an agent include output accuracy against approved references,\nprovenance completeness of retrieved information, explainability at the required review depth, and\ntimeliness within approved process windows. Critical process parameters — model version, prompt\nversion, retrieval scope, tool permissions, confidence thresholds, timeout and retry policy — are\nthe controlled inputs that materially influence those attributes, and treating them as informal\nsettings rather than controlled parameters is where AI agent governance breaks down.",[15,170,172],{"id":171},"a-stage-gated-rollout","A stage-gated rollout",[11,174,175],{},"Teams do not need to reach maturity level 5 before deploying AI agents responsibly. A structured\nrollout mirrors the phased approach used in process validation and CAPA management: map current\nmaturity, apply Quality by Design and critical-to-quality frameworks to define and measure agent\nperformance as a regulated process, verify continuously against defined attributes, and feed\nperformance findings into CAPA-style improvement cycles over time.",[11,177,178],{},"The fastest path to safe AI adoption in GMP is to govern agents with the same discipline already\nused for any critical process. The bedrock for AI agent governance already exists inside mature\nquality systems — the work now is structured adaptation, not reinvention.",[15,180,182],{"id":181},"related-reading","Related reading",[30,184,185,192,198],{},[33,186,187],{},[188,189,191],"a",{"href":190},"\u002Fblog\u002Fqxaios-compliance-centric-operating-model-for-ai-systems","QxAIOS: A Compliance-Centric Operating Model for AI Systems",[33,193,194],{},[188,195,197],{"href":196},"\u002Fblog\u002Foperating-ai-agents-in-gxp-qa-practitioners-guide","Operating AI Agents in GxP: A QA Practitioner's Guide",[33,199,200],{},[188,201,203],{"href":202},"\u002Fproduct\u002Fagentic-ai-governance","Governed AI pathway",{"title":205,"searchDepth":206,"depth":206,"links":207},"",2,[208,209,210,211,212,213],{"id":17,"depth":206,"text":18},{"id":24,"depth":206,"text":25},{"id":75,"depth":206,"text":76},{"id":160,"depth":206,"text":161},{"id":171,"depth":206,"text":172},{"id":181,"depth":206,"text":182},"AI Governance","2026-09-10","AI governance in pharma is not a greenfield problem. It is a quality-systems extension problem — mapping AI agent management maturity to QMS maturity that already exists.",false,null,"md",{},true,"\u002Fblog\u002Fpharma-does-not-need-a-new-ai-governance-religion",{"title":5,"description":216},"blog\u002Fpharma-does-not-need-a-new-ai-governance-religion",[226,227,228,229,230],"ai-governance","gmp","qms","ai-agents","quality-by-design","ufbstCZlnGivKyHIEPfyRDtTAmKJ5rIAkcSorXFGjJk",1789037363336]